C H Meyer, P Kroll, H-P Hammes. Show Affiliations »
Abstract
Entities: Chemical Disease Gene
Mesh： See more » Clinical Trials, Phase IV as TopicDiabetes Mellitus, Type 1/diagnosisDiabetes Mellitus, Type 1/drug therapyDiabetes Mellitus, Type 2/diagnosisDiabetes Mellitus, Type 2/drug therapyDiabetic Retinopathy/chemically inducedDiabetic Retinopathy/diagnosisDisease ProgressionHumansInsulin/analogs & derivativesInsulin/therapeutic useInsulin/toxicityInsulin GlargineInsulin, Isophane/therapeutic useInsulin, Isophane/toxicityInsulin, Long-ActingInsulin-Like Growth Factor I/metabolismRetinal Diseases/chemically inducedRetinal Diseases/diagnosisRetinal Vessels/drug effectsRetinal Vessels/pathologyUnited StatesUnited States Food and Drug AdministrationVascular Endothelial Growth Factor A/blood
Substances： See more » InsulinInsulin, Long-ActingVascular Endothelial Growth Factor AInsulin GlargineInsulin, IsophaneInsulin-Like Growth Factor I
Year: 2005 PMID： 15844050 DOI： 10.1055/s-2005-858075
Source DB: PubMed Journal: Klin Monbl Augenheilkd ISSN： 0023-2165 Impact factor: 0.700